BioVie Inc (NASDAQ:BIVI) will present blinded data from a Phase 3 clinical trial for NE3107 in Alzheimer's Disease at the 16th CTAD in Boston. The presentation will provide insights into the trial's cognitive, biomarker, and imaging findings. The data will be unveiled during an oral presentation on October 25, 2023, and further details will be shared once made public at the conference.
The Markets by Proactive
Go to Proactive Australia
Proactive’s Australian coverage continues on .com